OrbiMed Israel GP Ltd.
CIK 1569590 · last filed 2026-04-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NMTR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
HERZLIYA 46766
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACET | Director | 78,499 | $3.94 | $309.3K | -$5.40M | 2 | 2026-04-09 |
| BiomX Inc. (PHGE.WS) Delisted | Director | 2,813,489 | $0.01 | $24.8K | $242.5K | 3 | 2021-07-30 |
| 9 METERS BIOPHARMA, INC. (NMTR) Delisted | Director | 1,597 | $0.07 | $115 | -$41.87M | 6 | 2021-06-25 |
| CMMB | 10%+ Owner | 644,544 | $1.00 | $644.5K | $0 | 1 | 2021-03-18 |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Director | 73,650 | — | — | -$451.8K | 2 | 2020-12-04 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Director | 2,537,110 | — | — | $0 | 1 | 2017-05-11 |
Recent Filings · Page 2 of 2
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-09-17 | ACET | Grant (A) | +42,129,164 | $0 | EDGAR |
| 2020-07-02 | 9 METERS BIOPHARMA, INC. (NMTR) Delisted | Conv (C) | +13,573,000 | $0 | EDGAR |
| 2020-05-05 | 9 METERS BIOPHARMA, INC. (NMTR) Delisted | Buy (P) | — | $0 | EDGAR |
| 2019-12-20 | BiomX Inc. (PHGE.WS) Delisted | Buy (P) | +8,000 | $71.2K | EDGAR |
| 2019-12-09 | BiomX Inc. (PHGE.WS) Delisted | Buy (P) | +20,400 | $171.3K | EDGAR |
| 2019-05-06 | Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Buy (P) | +1,292,408 | $4.01M | EDGAR |
| 2017-05-11 | Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Grant (A) | +5,074,220 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.